Use of 40-O-(2-hydroxy)ethylrapamycin for treatment of restenosis and other disorders

• US 6,384,046 B1
• Filed: 11/14/2000
• Issued: 05/07/2002
• Est. Priority Date: 03/27/1996
• Status: Expired due to Term

• Current Assignee: Elata Limited (Qualcomm, Inc.)
• Original Assignee: Novartis Ag
• Inventors: Weckbecker, Gisbert, Schuler, Walter, Zerwes, Hans-Günter, Schuurman, Hendrik J.
• Primary Examiner(s): Jarvis, William R. A.
• Application Number:
  US09/712,359
• Time in Patent Office: 539 Days
• Field of Search: 514/291
• US Class Current: 514/291
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

This invention relates to the use of 40-O-(2-hydroxy)ethyl-rapamycin for the prevention or treatment of neointimal proliferation and thickening, restenosis, and vascular occlusion following vascular injury.

Claims

1. A method for preventing or treating:

neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following vascular injury comprising administering to a subject in need thereof an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin.

2. A method according to claim 1 for preventing or treating neointimal proliferation and thickening.

3. A method according to claim 1 for preventing or treating restenosis and/or vascular occlusion following vascular injury.

4. A method according to claim 1 for preventing or treating vascular occlusion following vascular injury.